Work

796TiP TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.2067

Authors: P. Grivas, C.N. Sternberg, N. Agarwal, D.P. Petrylak, S.T. Tagawa, Q. Hong, A. Gladden, C. Kanwal, T. Goswami, Y. Loriot

Institutions: University of Washington, Weill Cornell Medicine, Huntsman Cancer Institute, Yale University, Immunomedics (United States), Institut Gustave Roussy

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3088075463

FWCI: 1.145

Cites:

Cited by: 5

Related to: 10